Antithymocyte globulin facilitates alloreactive T-cell apoptosis by means of caspase-3: potential implications for monitoring rejection-free outcomes.
Chethan Ashokkumar, Qing Sun, Mylarappa Ningappa...
https://pubmed.ncbi.nlm.nih.gov/25531894Actively Recruiting
All Genders
ID01163578
Study of Biomarkers in Solid Organ and Bone Marrow Transplant Recipients to Better Treat Rejection
Led by University of Pittsburgh · Updated on 2025-09-09
1200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to understand how certain proteins expressed in biological tissues can help improve the understanding of drug effects used to treat rejection in transplant recipients. The study focuses on both solid organ and bone marrow transplant recipients and evaluates factors leading to rejection and outcomes without rejection. It is an observational study sponsored by the University of Pittsburgh. Participants provide various biological samples, including blood, saliva, urine, feces, bile, and leftover biopsy tissues from standard care procedures. Blood samples may be collected up to seven times within the first year after transplant and less frequently afterwards. Saliva samples are collected only if blood samples are not possible. These samples help assess biomarker expression and immune responses related to transplant rejection. Throughout the study, participants undergo periodic monitoring through blood and laboratory tests as part of their routine care. Researchers measure rejection severity at 90 days post-transplant and yearly immunosuppression thresholds. The study involves ongoing collection and analysis of biological samples to track biomarker changes over time, with participant involvement continuing indefinitely to support long-term research goals.
CONDITIONS
Brief Title
Biomarkers in Transplant Recipients to Improve Outcomes
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Recipients of abdominal, thoracic and bone marrow allografts receiving inpatient and outpatient follow-up with routine laboratory tests at the University of Pittsburgh Medical Center
- All ages
- Subject or parents are able to read and understand the informed consent
You will not qualify if you...
- Subjects and/or their parents who are unable to read and understand informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Long-term Monitoring
Duration - Indefinitely after transplantation
Participants who receive routine transplant care are observed over time. Blood samples may be collected up to 7 times within the first year and less often thereafter. Saliva samples may be collected up to 4 times if blood samples are unavailable or inadequate. Urine, feces, and bile samples may also be collected up to 4 times if needed. Biopsy specimens from standard care procedures may be used for additional testing when available. Biomarker measurements are evaluated from collected samples to assess immunosuppression and allograft function.
Samples collected during regular clinical tests and hospital admissions; frequency varies based on clinical care
Trial Site Locations
Total: 1 location
1
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States, 15224
Actively Recruiting
Loading map...
Research Team
M
Morgan L Paul, BSN
D
Daniel Pieratt, MPA
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Increased monocyte expression of sialoadhesin during acute cellular rejection and other enteritides after intestine transplantation in children.
Chethan Ashokkumar, Anna Gabriellan, Mylarappa Ningappa...
https://pubmed.ncbi.nlm.nih.gov/22249367